EUCTR2013-004489-32-DE进行中（未招募）不适用
An open label Randomised Phase II Trial of RNActive® Cancer Vaccine (CV9104) in high risk and intermediate risk patients with prostate cancer
CureVac AG0 个研究点开始时间: 2013年12月5日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1.Male aged = 18 years
- •2.Histologically confirmed localised adenocarcinoma of the prostate with at least one of the following criteria for intermediate to high risk disease:
- •Gleason Score 7-10
- •Serum PSA > 10,0 ng/mL
- •cT2b-c / cT3a without tumor fixation to adjacent organs
- •3.Absence of very high risk or metastatic disease (i.e. cT3b-T4 N0 or any T, N1 or M1) confirmed by EITHER CT or MRI of the abdomen and pelvis (in patients with a Gleason score = 8 or a clinical stage T3) and bone scintigraphy (in patients with a PSA of = 10 ng/mL, a Gleason score = 8, a clinical stage T3 or bone pain or other symptoms of metastatic disease)
- •4.Patient is physically fit and eligible for radical prostatectomy based on best clinical evidence and has already decided to undergo radical prostatectomy after discussion of potential alternative treatment options.
- •5.ECOG 0 or 1
- •6.No prior treatment for prostate cancer including prior surgery (including TURP ), pelvic lymph node dissection, radiation therapy, antihormonal therapy or chemotherapy
- •7.Adequate organ function:
- •Bone marrow function: hemoglobin = 12 g/dL; white blood cell count (WBC) = 3.0 x 109/L; lymphocyte count = 1.0 x 109/L; absolute neutrophil count (ANC) = 1.5 x 109/L; platelet count = 150 x 109/L
- •Hepatic: AST and ALT = 2.5 times upper limit of normal (ULN); bilirubin = 1.5 x ULN
- •Renal: creatinine = 2 mg/dL and creatinine clearance = 45 mL/min/1.73 m2
- •8.Fertile men and their female partners must use a highly effective method of contraception resulting in a low failure rate (i.e. less than 1% per year) when used consistently and correctly. Those methods include implants, injectables, combined oral contraceptives, some intrauterine devices (IUDs) or abstinence. The contraception should be applied from enrollment until 4 weeks after the last vaccination.
- •9.Written informed consent must be obtained prior to conducting any study-specific procedures.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 8
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 28
排除标准
- •1.Concurrent treatment with systemic steroids or other immunosuppressive agents [except topical (inhaled, topical, nasal) and replacement therapy for adrenal insufficiency] should be strictly avoided throughout the study, concomitant treatment with immunomodulating agents including herbal remedies (e.g. mistletoe extract) has to be avoided during study treatment and must be discontinued at least 28 days prior to the start of treatment
- •2.Previous therapies with investigational anticancer agents including cancer vaccines or other cancer immunotherapies
- •3.Prior splenectomy
- •4.Prior allogeneic bone marrow transplant
- •5.History of autoimmune disorders such as sarcoidosis, lupus erythematosus, rheumatoid arthritis, glomerulonephritis or systemic vasculitis (except autoimmune thyroiditis with only thyroid hormone replacement and stable disease > 1 year)
- •6.Primary or secondary immune deficiency
- •7.Seropositive for HIV, HBV (except after Hep B vaccination) or HCV infection
- •8.History of other malignancies over the last 5 years (except adequately treated basal cell or squamous cell carcinoma of the skin)
- •9.Uncontrolled medical condition considered as high risk for the treatment with an investigational drug including unstable diabetes mellitus, symptomatic congestive heart failure (NYHA 3 and 4); coronary heart disease with unstable angina pectoris, history of myocardial infarction, or coronary artery intervention (PTCA, stenting) within 6 months prior to enrolment; significant cardiac arrhythmia, history of stroke or transient ischemic attack. Severe hypertension according to WHO criteria or systolic blood pressure = 180 mmHg at the time of enrolment).
- •10.History of seizures, encephalitis or multiple sclerosis
- •11.History of inflammatory bowel disease or Crohn´s disease or ulcerative colitis
- •12.Active drug abuse or chronic alcoholism
- •13.Active skin disease (atopic eczema, psoriasis) in the areas for vaccine injection preventing the i.d. administration of study product into areas of healthy skin
- •14.Allergies to any component of the study drug including known allergy to protamine sulphate (e.g. allergy to protamine containing insulins) or fish allergy.
- •15.Prior vasectomy
- •16.Known type I allergy to ß-lactam antibiotics
- •17.Active infections (including acute prostatitis) requiring anti-infectious therapy at the time of enrolment. : leucocytosis = 9000/µL; CRP elevation = 2.5 times upper limit of normal or leucocyturia of = 75 cells/µl (equals = grade 2+ on two consecutive Combur® urinalysis specimen)
- •18.Uncontrolled urinary retention or hydronephrosis
- •19.Inability to provide informed consent due to mental impairment
研究者
相似试验
招募中
2 期
Study of efficacy and safety of JDQ443 as first-line treatment for patients with locally advanced or metastatic KRAS G12C- mutated non-small cell lung cancer with a PD-L1 expression 1% or a PD-L1 expression = 1% and an STK11 co-mutatioCTRI/2024/01/061436ovartis Healthcare Pvt Ltd
进行中（未招募）
1 期
An open label, randomized, phase 2 study of the anti-Programmed Death-Ligand 1 (PD-L1) Durvalumab, alone or in combination with Tremelimumab, in patients with advanced and relapsed germ cell tumorsAdvanced and relapsed germ cell tumorsMedDRA version: 21.1Level: PTClassification code 10068971Term: Germ cell cancer metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-001688-35-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI120
进行中（未招募）
1 期
ECX + Panitumumab vs. ECX alone in subjects with locally advanced gastric cancer or cancer of the gastroesophageal junctioSubjects with Locally Advanced Gastric Cancer or Cancer of the Gastroesophageal JunctionMedDRA version: 18.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 18.0Level: LLTClassification code 10056267Term: Gastroesophageal cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-007798-18-DEAIO-Studien-gGmbH
进行中（未招募）
1 期
Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARPeoadjuvant TNBCMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2010-018960-17-DEsanofi-aventis recherche & développement
进行中（未招募）
1 期
Randomized, open-label, phase 2 study of the efficacy and safety of weekly paclitaxel single-agent and two different regimens of the PARP-1 inhibitor SAR240550 (BSI-201) in combination with weekly paclitaxel, as neoadjuvant therapy in patients with Stage II-IIIA triple negative breast cancer (TNBC) - SOLTI NEOPARPeoadjuvant TNBCMedDRA version: 12.1Level: LLTClassification code 10057654Term: Breast cancer femaleEUCTR2010-018960-17-FRsanofi-aventis recherche & développement